Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: J Surg Res. 2017 May 8;220:438–443. doi: 10.1016/j.jss.2017.04.028

Table 2.

Blood Product use in Patients Undergoing MT

No-TXA (n=25) TXA (n=18) P
RBC 19 (13–28) 28 (17–51) 0.036
FFP 8 (6–15) 15 (14–28) 0.003
PLT 2 (1–3) 3 (2–9) 0.124
CRYO 0 (0–2) 2 (1–4) 0.024
NISS 38 (34–50) 50 (39–57) 0.104
Mortality 40% 61% 0.346